---
title: "Hoth Therapeutics, Inc. (HOTH.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/HOTH.US.md"
symbol: "HOTH.US"
name: "Hoth Therapeutics, Inc."
industry: "Pharmaceuticals"
---

# Hoth Therapeutics, Inc. (HOTH.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | US Market |
| Website | [oththerapeutics.com](https://oththerapeutics.com) |

## Company Profile

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of ...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.32 | 111/257 | - | - | - |
| PB | 1.90 | 84/257 | 2.02 | 1.74 | 1.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-04T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.02 |
| Highest Target | 5.00 |
| Lowest Target | 5.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/HOTH.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/HOTH.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/HOTH.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.